Seres Therapeutics, Inc. (NASDAQ:MCRB) Position Boosted by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,100,000 shares of the biotechnology company’s stock after purchasing an additional 100,000 shares during the period. Handelsbanken Fonder AB owned about 0.85% of Seres Therapeutics worth $1,540,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of MCRB. Hudson Bay Capital Management LP lifted its position in shares of Seres Therapeutics by 127.3% during the third quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after purchasing an additional 1,119,800 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in Seres Therapeutics by 731.3% in the third quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock worth $492,000 after acquiring an additional 181,957 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in Seres Therapeutics by 21.1% in the third quarter. Rafferty Asset Management LLC now owns 936,382 shares of the biotechnology company’s stock worth $2,229,000 after acquiring an additional 162,995 shares during the last quarter. Dark Forest Capital Management LP bought a new position in Seres Therapeutics in the third quarter worth about $280,000. Finally, Barclays PLC lifted its holdings in Seres Therapeutics by 24.3% in the third quarter. Barclays PLC now owns 461,209 shares of the biotechnology company’s stock worth $1,097,000 after acquiring an additional 90,304 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Price Performance

NASDAQ MCRB opened at $0.83 on Friday. Seres Therapeutics, Inc. has a 12 month low of $0.54 and a 12 month high of $6.65. The firm has a market capitalization of $124.58 million, a PE ratio of -0.92 and a beta of 2.23. The company’s 50 day simple moving average is $0.84 and its 200 day simple moving average is $1.09.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts anticipate that Seres Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on MCRB shares. Oppenheimer dropped their price target on shares of Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 6th. Chardan Capital lowered their price objective on shares of Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.